Lactic acid- Stayble TherapeuticsAlternative Names: STA 363
Latest Information Update: 30 Jan 2017
At a glance
- Originator Stayble Therapeutics
- Class Analgesics; Hydroxy acids; Lactates
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Back pain
Most Recent Events
- 11 Jan 2017 Phase-I/II clinical trials in Back pain in Sweden (Intraspinal)